Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Athena Diagnostics Inc | RCV000992764 | SCV001145291 | uncertain significance | not provided | 2018-12-28 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV002549805 | SCV003443252 | uncertain significance | RYR1-Related Disorders | 2022-11-22 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 4917 of the RYR1 protein (p.Phe4917Leu). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RYR1 protein function. ClinVar contains an entry for this variant (Variation ID: 805278). This missense change has been observed in individual(s) with autosomal dominant congenital myopathy (PMID: 23394784). This variant is not present in population databases (gnomAD no frequency). |